便秘：利那洛肽——一种用于慢性便秘的新型刺激性药物。 - Suppr

Suppr

超能文献

Constipation: Linaclotide--a stimulating new drug for chronic constipation.

作者信息

Harris Lucinda A

出版信息

Nat Rev Gastroenterol Hepatol. 2010 Jul;7(7):365-6. doi: 10.1038/nrgastro.2010.84.

DOI:10.1038/nrgastro.2010.84

PMID:20606631

Abstract

摘要

相似文献

Constipation: Linaclotide--a stimulating new drug for chronic constipation.

Nat Rev Gastroenterol Hepatol. 2010 Jul;7(7):365-6. doi: 10.1038/nrgastro.2010.84.

Two randomized trials of linaclotide for chronic constipation.

N Engl J Med. 2011 Aug 11;365(6):527-36. doi: 10.1056/NEJMoa1010863.

Clarification of trial end points presented in a recent review of linaclotide.

Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):13-4; author reply 15. doi: 10.1586/egh.11.89.

Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.

Dig Liver Dis. 2013 Sep;45(9):724-6. doi: 10.1016/j.dld.2013.03.017. Epub 2013 May 21.

Linaclotide: first global approval.

Drugs. 2012 Nov 12;72(16):2167-75. doi: 10.2165/11470590-000000000-00000.

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):301-10. doi: 10.1586/egh.11.30.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.

Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.

Future Med Chem. 2013 Mar;5(3):291-300. doi: 10.4155/fmc.13.5.

Pilot study on the effect of linaclotide in patients with chronic constipation.

Am J Gastroenterol. 2009 Jan;104(1):125-32. doi: 10.1038/ajg.2008.59.

Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Mini Rev Med Chem. 2013 Oct;13(11):1685-90. doi: 10.2174/1389557511313110011.

本文引用的文献

Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.

Am J Gastroenterol. 2010 Apr;105(4):731-5. doi: 10.1038/ajg.2010.12.

Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID.

Am J Gastroenterol. 2010 Apr;105(4):722-30. doi: 10.1038/ajg.2010.49.

Efficacy of linaclotide for patients with chronic constipation.

Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.

Emerging drugs for chronic constipation.

Expert Opin Emerg Drugs. 2009 Sep;14(3):493-504. doi: 10.1517/14728210903146890.

Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.

Am J Gastroenterol. 2008 Apr;103(4):815-9. doi: 10.1111/j.1572-0241.2008.01818.x.

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Gastroenterology. 2007 Sep;133(3):761-8. doi: 10.1053/j.gastro.2007.06.067. Epub 2007 Jul 3.

Systematic review on the management of chronic constipation in North America.

Am J Gastroenterol. 2005;100 Suppl 1:S5-S21. doi: 10.1111/j.1572-0241.2005.50613_2.x.

Physician visits in the United States for constipation: 1958 to 1986.

Dig Dis Sci. 1989 Apr;34(4):606-11. doi: 10.1007/BF01536339.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验